Considering the continued shortage of Fluoxetine 10mg tablets, the Department of Health and Social Care (DHSC) has further extended the serious shortage protocol (SSP) for the medicine to May 13, 2022.
Earlier the SSP for Fluoxetine 10mg tablets was set to expire today (February 11).
The Pharmaceutical Services Negotiating Committee (PSNC) has secured an extension to the transition period by three months. With this, the NHSBSA will continue to accept the No Cheaper Stock Obtainable (NCSO) endorsement and allow SSP claims on tokens until February 2022.
From February 2022, all contractors must use the ‘SSP’ endorsement, PSNC stated.
Reimbursement
The negotiator has informed that the reimbursement is for the medicine supplied in accordance with the SSP and not the originally prescribed medicine.
The reimbursement price will account for VAT payment and supply in accordance with the SSP would incur the following fees on the contractor:
- One Single Activity fee (currently £1.29)
- One SSP fee (£5.35)
